A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood.

Abstract

BACKGROUND:

Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas.

METHODS:

We conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma. Eligible patients received a fixed daily dose of 0.15 mg/kg of ATO once a week, with each subsequent cohort of patients receiving an additional dose per week up to a planned frequency of ATO administration 5 days per week as tolerated. Twenty-four children were enrolled and 21 children were evaluable.

RESULTS:

ATO was well tolerated throughout the entire dose escalation, resulting in confirmation of safety when administered 5 days per week during irradiation.

CONCLUSIONS:

The recommended dose of ATO during conventional irradiation is 0.15 mg/kg given on a daily basis with each fraction of radiation therapy administered.

• Authors: Kenneth J Cohen, Iris C Gibbs, Paul G Fisher, Robert J Hayashi, Margaret E Macy, Lia Gore
• Journal: Neuro-oncology (Neuro Oncol) Vol. 15 Issue 6 Pg. 783-7 (Jun 2013) ISSN: 1523-5866 [Electronic] England
• PMID: 23460318 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Arsenicals
• Oxides
• Arsenic Trioxide

Topics

• Adolescent
• Adult
• Antineoplastic Agents (therapeutic use)
• Arsenic Trioxide
• Arsenicals (therapeutic use)
• Astrocytoma (mortality, pathology, therapy)
• Brain Stem Neoplasms (mortality, pathology, therapy)
• Chemoradiotherapy
• Child
• Child, Preschool
• Dose Fractionation, Radiation
• Female
• Follow-Up Studies
• Humans
• Male
• Neoplasm Grading
• Oxides (therapeutic use)
• Prognosis
• Survival Rate
• Young Adult